Clinical Trial Update: Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating conversion therapy with Camrelizumab plus chemoradiotherapy in patients with initially unresectable gastric or GEJ adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN